Publications

Search our bibliography using the filters on the right-hand side.

Displaying 101 through 125 of 125 publications.

Martin-Richard M, Gallego R, Pericay C, Garcia Foncillas JG, Queralt B, Casado E, Barriuso J, Iranzo V, Juez I, Visa L, Saigi E, Barnadas A, Garcia-Albeniz X, Maurel J. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study. Invest New Drugs. 2013 Dec;31(6):1573-9.

Sommer WH, Ceelen F, Garcia-Albeniz X, Paprottka PM, Auernhammer CJ, Armbruster M, Nikolaou K, Haug AR, Reiser MF, Theisen D. Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin. Eur Radiol. 2013 Nov;23(11):3094-103. doi: 10.1007/s00330-013-2925-8

Garcia-Albeniz X, Rudolph A, Hutter CM, Lin Y, White E, Brenner H, Casey G, Gallinger S, Hsu L, Hudson TJ, Le Marchand L, Potter J, Slattery M, Zanke B, Newcomb PA, Chan AT, Peters U, Chang-Claude J. Genome wide gene-environment interaction study identifies a CYP24A1-related variant as a modifier of colorectal cancer risk associated with menopausal estrogen plus progesterone therapy. Presented at the 2013 American Society for Human Genetics Annual Meeting; October 24, 2013. Boston, MA.

Codony-Servat J, Marin-Aguilera M, Visa L, Garcia-Albeniz X, Pineda E, Fernandez PL, Filella X, Gascon P, Mellado B. Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer. Prostate. 2013 Apr;73(5):512-21. doi: 10.1002/pros.22591

Codony-Servat J, Garcia-Albeniz X, Pericay C, Alonso V, Escudero P, Fernandez-Martos C, Gallego R, Martinez-Cardus A, Martinez-Balibrea E, Maurel J. Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer. Med Oncol. 2013 Mar;30(1):428. doi: 10.1007/s12032-012-0428-0

Garcia-Albeniz X, Nan H, Valeri L, Morikawa T, Kuchiba A, Phipps AI, Hutter CM, Peters U, Newcomb PA, Fuchs CS, Giovannucci EL, Ogino S, Chan AT. Phenotypic and tumor molecular characterization of colorectal cancer in relation to a susceptibility SMAD7 variant associated with survival. Carcinogenesis. 2013 Feb;34(2):292-8. doi: 10.1093/carcin/bgs335

Phipps AI, Newcomb PA, Garcia-Albeniz X, Hutter CM, White E, Fuchs CS, Hazra A, Ogino S, Nan H, Ma J, Campbell PT, Figueiredo JC, Peters U, Chan AT. Association between colorectal cancer susceptibility loci and survival time after diagnosis with colorectal cancer. Gastroenterology. 2012 Jul;143(1):51-4. doi: 10.1053/j.gastro.2012.04.052

Alonso-Espinaco V, Marmol M, Alonso V, Escudero P, Horndler C, Ortego J, Gallego R, Garcia-Albeniz X, Jares P, Cuatrecasas M, Jose Lozano J, Castells A, Maurel J. Influence of BRAF mutations and RAC1b/RAC1 mRNA expression ratio on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy. Poster presented at the 2012 ASCO Annual Meeting; June 4, 2012. Chicago, IL. [abstract] J Clin Oncol. 2012 Jun; 30(15_Suppl):3553. doi: 10.1200/jco.2012.30.15_suppl.3553

Garcia-Albeniz X, Chan AT. Aspirin for the prevention of colorectal cancer. Best Pract Res Clin Gastroenterol. 2011 Aug;25(0):461-72. doi: 10.1016/j.bpg.2011.10.015

Maurel J, Garcia-Albeniz X, Mendez Mendez C, Martin-Richard M, Pericay C, Vera R, Aparicio J, Rubini M, Cuatrecasas M. PULSE: An open-label, phase II study assessing double positivity (phospho-insulin-growth factor receptor-1 [pIGF-IR] and matrilysin [MMP7]) expression, as a predictive marker of resistance in previously untreated metastatic colorectal cancer (mCRC) wild-type KRAS patients (pts) treated with panitumumab plus mFOLFOX6—A GEMCAD study. Poster presented at the 2011 ASCO Annual Meeting; June 6, 2011. Chicago, IL. [abstract] J Clin Oncol. 2011 Jun; 29(15_suppl). doi: 10.1200/jco.2011.29.15_suppl.tps164

Carrera G, Garcia-Albeniz X, Ayuso JR, Aparicio J, Castells A, Codony-Servat J, Feliu J, Fuster D, Gallego R, Pages M, Torres F, Maurel J. Design and endpoints of clinical and translational trials in advanced colorectal cancer. a proposal from GROUP Español Multidisciplinar en Cancer Digestivo (GEMCAD). Rev Recent Clin Trials. 2011 May;6(2):158-70. doi: 10.2174/157488711795177868

Garcia-Albeniz X, Pericay C, Alonso-Espinaco V, Alonso V, Escudero P, Fernandez- Martos C, Gallego R, Gascon P, Castellvi-Bel S, Maurel J. Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab. Tumour Biol. 2011 Apr;32(2):417-24. doi: 10.1007/s13277-010-0136-3

Horndler C, Gallego R, Garcia-Albeniz X, Alonso-Espinaco V, Alonso V, Escudero P, Jimeno M, Ortego J, Codony-Servat J, Fernandez-Martos C, Calatrava A, Marín-Aguilera M, Munoz J, Castellví-Bel S, Castells A, Rubini M, Gascon P, Maurel J. Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study. Cancer Biol Ther. 2011 Jan 15;11(2):177-83.

Gonzalez-Roca E, Garcia-Albeniz X, Rodriguez-Mulero S, Gomis RR, Kornacker K, Auer H. Accurate expression profiling of very small cell populations. PLoS One. 2010 Dec 28;5(12):e14418. doi: 10.1371/journal.pone.0014418

Maurel J, Martins AS, Poveda A, Lopez-Guerrero JA, Cubedo R, Casado A, Martinez-Trufero J, Ramon Ayuso J, Lopez-Pousa A, Garcia-Albeniz X, Garcia del Muro X, de Alava E. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas. Cancer. 2010 Aug 1;116(15):3692-701. doi: 10.1002/cncr.25111

Garcia-Alvarez A, Sitges M, Garcia-Albeniz X, Sionis A, Loma-Osorio P, Bosch X. Atypical cardiac manifestation of hypereosinophilic syndrome and reversible cardiotoxicity to imatinib. Int J Cardiol. 2010 Mar 4;139(2):e29-31. doi: 10.1016/j.ijcard.2008.11.018

Garcia-Alvarez A, Garcia-Albeniz X, Esteve J, Rovira M, Bosch X. Cardiotoxicity of tyrosine-kinase-targeting drugs. Cardiovasc Hematol Agents Med Chem. 2010 Jan;8(1):11-21.

Petit A, Castillo M, Gaspa A, Colomer D, Garcia de Albeniz X, Moreno C, Camos M, Mellado B, Mallofre C. Expression and mutational analyses of KIT and PDGFR-alpha in sarcomatoid renal cell carcinoma. Histopathology. 2009 Aug;55(2):230-2. doi: 10.1111/j.1365-2559.2009.03342.x

Martinez-Fernandez A, Garcia-Albeniz X, Pineda E, Visa L, Gallego R, Codony-Servat J, Auge JM, Longaron R, Gascon P, Lacy A, Castells A, Maurel J. Serum matrilysin levels predict outcome in curatively resected colorectal cancer patients. Ann Surg Oncol. 2009 May;16(5):1412-20. doi: 10.1245/s10434-009-0405-9

Gallego R, Codony-Servat J, Garcia-Albeniz X, Carcereny E, Longaron R, Oliveras A, Tosca M, Auge JM, Gascon P, Maurel J. Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer. Endocr Relat Cancer. 2009 Mar;16(1):311-7. doi: 10.1677/ERC-08-0250

Garcia-Albeniz X, Martinez-Fernandez A, Gascon P. Combining targeted therapies. Target Oncol. 2007 Oct;2(4):241-52. doi: 10.1007/s11523-007-0062-5

Maurel J, Nadal C, Garcia-Albeniz X, Gallego R, Carcereny E, Almendro V, Marmol M, Gallardo E, Maria Auge J, Longaron R, Martinez-Fernandez A, Molina R, Castells A, Gascon P. Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer. 2007 Sep 1;121(5):1066-71.

Domingo-Domenech J, Castel T, Auge JM, Garcia-Albeniz XA, Conill C, Puig S, Vilella R, Matas J, Malvehy J, Gascon P, Mellado B, Molina R. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients. Tumour Biol. 2007;28(5):264-82.

Garcia-Albeniz X, Guerra-Gutierrez F, Ortega-Martinez R, Sanchez-Víllegas A, Martinez-Gonzalez MA. Tobacco consumption in university graduates. Gac Sanit. 2004 Mar;18(2):108-17.

Plaza Cano MM, Garcia de Albeniz Martinez XA, de Andres Copa P, Braun Saro B, Suarez Alvarez C, Garcia de Aguinaga ML, Estirado de Cabo E, Guinea Esquerdo J, Posada de la Paz M. Diagnostic performance of echocardiography in the follow-up of patients with toxic oil syndrome. Rev Esp Cardiol. 2003 Dec;56(12):1195-201.